Literature DB >> 12013178

Pegylated recombinant human epidermal growth factor (rhEGF) for sustained release from biodegradable PLGA microspheres.

Tae Hyoung Kim1, Haeshin Lee, Tae Gwan Park.   

Abstract

Recombinant human epidermal growth factor (rhEGF) was conjugated with polyethylene glycol (PEG) to improve its physical stability during microencapsulation in biodegradable poly(lactic-co-glycolic acid) microspheres. rhEGF was conjugated with N-hydroxysuccimide (NHS)-derivatized methoxy-PEG (mPEG) of MW 2000 and 5000 under various reaction conditions to optimize the extent of pegylation. Pegylated rhEGF showed much enhanced physical stability against homogenization. Pegylated rhEGF was encapsulated in PLGA microspheres by a double emulsion solvent evaporation method to achieve a sustained release. Pegylated rhEGF exhibited a tri-phasic release profile with a reduced initial burst, compared with unpegylated rhEGF. This study demonstrated that protein pegylation enhanced physical stability of protein and could be a good approach to achieve a sustained protein release profile from biodegradable microspheres.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12013178     DOI: 10.1016/s0142-9612(01)00365-9

Source DB:  PubMed          Journal:  Biomaterials        ISSN: 0142-9612            Impact factor:   12.479


  9 in total

1.  Control of drug loading efficiency and drug release behavior in preparation of hydrophilic-drug-containing monodisperse PLGA microspheres.

Authors:  Fuminori Ito; Hiroyuki Fujimori; Hiroyuki Honnami; Hiroyoshi Kawakami; Kiyoshi Kanamura; Kimiko Makino
Journal:  J Mater Sci Mater Med       Date:  2010-02-03       Impact factor: 3.896

2.  Loading PEG-catalase into filamentous and spherical polymer nanocarriers.

Authors:  Eric A Simone; Thomas D Dziubla; Evguenia Arguiri; Vanessa Vardon; Vladimir V Shuvaev; Melpo Christofidou-Solomidou; Vladimir R Muzykantov
Journal:  Pharm Res       Date:  2008-10-28       Impact factor: 4.200

3.  Preparation and stability of poly(ethylene glycol) (PEG)ylated octreotide for application to microsphere delivery.

Authors:  Dong Hee Na; Santos B Murty; Kang Choon Lee; B C Thanoo; Patrick P DeLuca
Journal:  AAPS PharmSciTech       Date:  2003-12-31       Impact factor: 3.246

4.  N-terminal site-specific mono-PEGylation of epidermal growth factor.

Authors:  Haeshin Lee; Il Ho Jang; Sung Ho Ryu; Tae Gwan Park
Journal:  Pharm Res       Date:  2003-05       Impact factor: 4.200

5.  Kinetic degradation and biocompatibility evaluation of polycaprolactone-based biologics delivery matrices for regenerative engineering of the rotator cuff.

Authors:  Anupama Prabhath; Varadraj N Vernekar; Vignesh Vasu; Mary Badon; Jean-Emmanuel Avochinou; Alexandru D Asandei; Sangamesh G Kumbar; Eckhard Weber; Cato T Laurencin
Journal:  J Biomed Mater Res A       Date:  2021-05-11       Impact factor: 4.396

6.  Dimensionality reduction, and function approximation of poly(lactic-co-glycolic acid) micro- and nanoparticle dissolution rate.

Authors:  Varun Kumar Ojha; Konrad Jackowski; Ajith Abraham; Václav Snášel
Journal:  Int J Nanomedicine       Date:  2015-02-04

7.  The Stability Maintenance of Protein Drugs in Organic Coatings Based on Nanogels.

Authors:  Hongzhao Qi; Lijun Yang; Peipei Shan; Sujie Zhu; Han Ding; Sheng Xue; Yin Wang; Xubo Yuan; Peifeng Li
Journal:  Pharmaceutics       Date:  2020-02-01       Impact factor: 6.321

8.  Microencapsulation of PEGylated adenovirus within PLGA microspheres for enhanced stability and gene transfection efficiency.

Authors:  Hyejung Mok; Ji Won Park; Tae Gwan Park
Journal:  Pharm Res       Date:  2007-10-11       Impact factor: 4.580

9.  Preparation, characterization, in vitro release and degradation of cathelicidin-BF-30-PLGA microspheres.

Authors:  Lili Li; Qifeng Wang; Hongli Li; Mingwei Yuan; Minglong Yuan
Journal:  PLoS One       Date:  2014-06-25       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.